Clinic
York Hospital
York Hospital was paid $5.88M by Medicaid between Jan 2018 and Dec 2024, across 287 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 29% of everything it billed.
33Billing provider infoYORK HOSPITAL
YORK, ME 03909
YORK, ME 03909
33aNPI1376528398assigned 12/13/2005
33bProvider typeClinic/Center
28Total paid$5.88M
24GClaims680,874
24DCodes billed287
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinic/Center providers in Maine
Rank by total paid#2 of 16
Median peer was paid$49K
This provider vs. median120×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 78,408 | $550K | |
| 2019 | 91,126 | $649K | |
| 2020 | 84,611 | $565K | |
| 2021 | 121,068 | $783K | |
| 2022 | 116,610 | $885K | |
| 2023 | 102,909 | $802K | |
| 2024incomplete | 86,142 | $1.64M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 29% | 47,603 | 44,023 | $1.69M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 15% | 20,835 | 19,288 | $859K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 12% | 77,544 | 59,524 | $711K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 4.0% | 4,529 | 3,968 | $238K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.0% | 4,731 | 4,235 | $235K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 3.3% | 5,127 | 4,466 | $192K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 2.6% | 5,682 | 5,208 | $153K |
| Q3014 | Telehealth originating site facility fee | 2.3% | 16,101 | 9,519 | $136K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | 2.0% | 1,732 | 1,005 | $119K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.4% | 1,563 | 974 | $85K |
| 71046 | Radiologic examination, chest; 2 views | 1.3% | 7,044 | 6,521 | $77K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.3% | 1,757 | 1,629 | $74K |
275 more codes
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 1.2% | 18,818 | $69K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.1% | 19,818 | $64K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.0% | 2,337 | $62K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 1,176 | $58K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 13,167 | $57K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,069 | $48K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,971 | $41K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,743 | $36K |
| 64615 | <1% | 1,001 | $35K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,672 | $34K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 527 | $28K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,688 | $28K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 8,016 | $26K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 6,422 | $24K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,938 | $24K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 2,271 | $23K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 12,918 | $23K |
| 80053 | Comprehensive metabolic panel | <1% | 25,208 | $23K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 3,520 | $20K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 30,464 | $20K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 896 | $20K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 373 | $19K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,350 | $19K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,229 | $18K |
| 97161 | <1% | 2,445 | $17K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 5,843 | $17K |
| 93017 | <1% | 355 | $16K | |
| 97597 | <1% | 871 | $15K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 11,593 | $14K |
| G0008 | Administration of influenza virus vaccine | <1% | 1,706 | $11K |
| 73630 | <1% | 1,593 | $11K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,105 | $10K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 464 | $10K |
| 87428 | <1% | 966 | $9K | |
| 99443 | <1% | 325 | $9K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,885 | $9K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 1,520 | $9K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 2,475 | $8K |
| 73562 | <1% | 685 | $8K | |
| 80061 | Lipid panel | <1% | 9,308 | $8K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,650 | $7K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 6,499 | $7K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 7,648 | $7K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 38 | $6K |
| 76830 | Ultrasound, transvaginal | <1% | 576 | $6K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 654 | $6K |
| 71250 | <1% | 213 | $6K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 862 | $6K |
| 97162 | <1% | 908 | $6K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,059 | $6K |
| 93296 | <1% | 626 | $6K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 34,204 | $6K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,418 | $5K |
| 73610 | <1% | 924 | $5K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,363 | $5K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,211 | $5K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 8,721 | $5K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,204 | $5K |
| 73110 | <1% | 343 | $5K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 875 | $5K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 610 | $5K |
| 97035 | <1% | 4,847 | $5K | |
| 72100 | <1% | 416 | $5K | |
| 73030 | <1% | 622 | $5K | |
| 99442 | <1% | 376 | $5K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,847 | $5K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,229 | $4K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 102 | $4K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 48 | $4K |
| 82607 | <1% | 3,176 | $4K | |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 74 | $4K |
| 82728 | <1% | 2,879 | $3K | |
| 96160 | <1% | 543 | $3K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,135 | $3K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 824 | $3K |
| 99001 | <1% | 10,693 | $3K | |
| 90677 | <1% | 318 | $3K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,367 | $3K |
| 84439 | <1% | 3,136 | $3K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 146 | $3K |
| 87081 | <1% | 6,208 | $3K | |
| 84484 | <1% | 2,377 | $3K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,902 | $3K |
| 93975 | <1% | 13 | $3K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,978 | $3K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 2,038 | $2K |
| 73130 | <1% | 264 | $2K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 39 | $2K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,453 | $2K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,028 | $2K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 132 | $2K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,695 | $2K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 38 | $2K |
| 90480 | <1% | 147 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,489 | $2K |
| 81025 | <1% | 4,522 | $2K | |
| 83550 | <1% | 2,860 | $2K | |
| 83540 | <1% | 2,981 | $2K | |
| 83880 | <1% | 403 | $2K | |
| 87660 | <1% | 1,080 | $2K | |
| 87077 | <1% | 2,247 | $2K | |
| 87480 | <1% | 1,081 | $2K | |
| 87510 | <1% | 1,081 | $2K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,833 | $1K |
| 71045 | Radiologic examination, chest; single view | <1% | 205 | $1K |
| 87186 | <1% | 2,122 | $1K | |
| 59025 | Fetal non-stress test | <1% | 187 | $1K |
| G0378 | Hospital observation service, per hour | <1% | 100 | $1K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,250 | $1K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,431 | $1K |
| 76770 | <1% | 46 | $1K | |
| 97116 | <1% | 1,015 | $1K | |
| 82746 | <1% | 1,039 | $1K | |
| 73502 | <1% | 155 | $1K | |
| 81003 | <1% | 6,776 | $1K | |
| 74018 | <1% | 44 | $1K | |
| 83735 | <1% | 2,624 | $1K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 2,167 | $1K |
| 83690 | <1% | 2,622 | $1K | |
| 96161 | <1% | 1,662 | $1K | |
| 36591 | <1% | 177 | $1K | |
| 96367 | <1% | 121 | $1K | |
| 94060 | <1% | 50 | $1K | |
| 94726 | <1% | 93 | $1K | |
| 86618 | <1% | 804 | $1K | |
| 96415 | <1% | 80 | $1K | |
| 86703 | <1% | 1,001 | $1K | |
| 76801 | <1% | 134 | $1K | |
| 85610 | <1% | 4,023 | $1K | |
| 76642 | <1% | 149 | $1K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 2,037 | $1K |
| 90715 | <1% | 2,271 | $1K | |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | <1% | 689 | $1K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 12 | $993.28 |
| 80306 | <1% | 977 | $992.20 | |
| 97165 | <1% | 249 | $964.35 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 368 | $919.17 |
| 86803 | <1% | 1,358 | $916.72 | |
| 71271 | <1% | 66 | $915.44 | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 44 | $882.57 |
| 90662 | <1% | 657 | $873.22 | |
| 82784 | <1% | 556 | $846.99 | |
| 86140 | <1% | 2,236 | $820.03 | |
| 85651 | <1% | 2,512 | $796.03 | |
| A9270 | Non-covered item or service | <1% | 1,263 | $784.47 |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 382 | $768.49 |
| 96127 | <1% | 1,460 | $730.57 | |
| 81002 | <1% | 3,177 | $723.10 | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 295 | $712.92 |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 226 | $677.64 |
| 88342 | <1% | 206 | $616.48 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 702 | $611.69 |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 172 | $606.89 |
| 86900 | <1% | 1,137 | $602.62 | |
| 84481 | <1% | 270 | $590.75 | |
| 86850 | <1% | 1,012 | $569.16 | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 12 | $534.17 |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 53 | $531.10 |
| 90651 | <1% | 677 | $516.12 | |
| 90670 | <1% | 1,916 | $512.78 | |
| 87070 | <1% | 1,029 | $485.96 | |
| 87340 | <1% | 1,240 | $474.26 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 4,681 | $441.44 |
| 95251 | <1% | 42 | $434.14 | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 14 | $418.13 |
| 90686 | <1% | 5,488 | $410.94 | |
| 82043 | <1% | 614 | $400.64 | |
| 0072A | <1% | 86 | $400.00 | |
| 0071A | <1% | 90 | $400.00 | |
| 80305 | <1% | 1,340 | $386.79 | |
| 93018 | <1% | 62 | $382.73 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 88 | $373.21 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,120 | $358.02 |
| 87430 | <1% | 982 | $356.28 | |
| 87420 | <1% | 429 | $353.46 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 427 | $326.97 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 1,677 | $313.53 |
| 86901 | <1% | 1,139 | $290.17 | |
| 93016 | <1% | 28 | $279.41 | |
| 90656 | <1% | 181 | $276.86 | |
| 90734 | <1% | 485 | $275.02 | |
| 94729 | <1% | 92 | $274.85 | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 67 | $267.85 |
| 82947 | <1% | 1,209 | $253.57 | |
| 86038 | <1% | 297 | $237.57 | |
| 80076 | <1% | 513 | $237.28 | |
| 73140 | <1% | 96 | $228.13 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 58 | $201.84 |
| 93971 | <1% | 14 | $201.42 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 12 | $195.39 |
| 84460 | <1% | 521 | $190.97 | |
| 86592 | <1% | 813 | $189.11 | |
| 85730 | <1% | 417 | $182.29 | |
| 0011A | <1% | 886 | $181.08 | |
| 87147 | <1% | 687 | $176.77 | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 14 | $168.16 |
| 81001 | <1% | 911 | $156.52 | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 401 | $138.65 |
| 90474 | <1% | 1,015 | $138.41 | |
| 87653 | <1% | 85 | $137.16 | |
| 90710 | <1% | 86 | $131.56 | |
| 84403 | <1% | 137 | $127.63 | |
| 90694 | <1% | 74 | $126.15 | |
| 87469 | <1% | 12 | $122.80 | |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | <1% | 27 | $118.80 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 147 | $116.07 |
| 83516 | <1% | 128 | $111.89 | |
| 0012A | <1% | 866 | $107.60 | |
| 84702 | <1% | 169 | $104.72 | |
| 84450 | <1% | 337 | $103.53 | |
| 86762 | <1% | 120 | $95.15 | |
| 51798 | <1% | 13 | $75.35 | |
| 87205 | <1% | 392 | $73.31 | |
| 86706 | <1% | 122 | $71.57 | |
| 91322 | <1% | 57 | $61.53 | |
| 99406 | <1% | 14 | $59.52 | |
| 90698 | <1% | 1,599 | $55.20 | |
| 90680 | <1% | 1,082 | $51.06 | |
| 87088 | <1% | 227 | $48.45 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 68 | $48.30 |
| 83615 | <1% | 62 | $47.49 | |
| 99173 | <1% | 12 | $42.30 | |
| 0001A | <1% | 33 | $40.00 | |
| 0002A | <1% | 64 | $40.00 | |
| 84153 | <1% | 27 | $38.27 | |
| 86431 | <1% | 56 | $32.46 | |
| 98929 | <1% | 156 | $30.84 | |
| 82565 | <1% | 80 | $27.34 | |
| 82570 | <1% | 44 | $26.80 | |
| 90633 | <1% | 1,023 | $24.84 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 2,607 | $22.72 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 40 | $21.29 |
| 73070 | <1% | 14 | $17.67 | |
| 84550 | <1% | 15 | $16.42 | |
| 99000 | <1% | 104 | $15.95 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 31 | $15.64 |
| 87040 | <1% | 25 | $14.59 | |
| 86376 | <1% | 29 | $13.29 | |
| 84165 | <1% | 12 | $13.18 | |
| 82950 | <1% | 64 | $8.68 | |
| 82948 | <1% | 40 | $7.61 | |
| 84402 | <1% | 15 | $5.09 | |
| A9578 | Injection, gadobenate dimeglumine (multihance multipack), per ml | <1% | 14 | $2.21 |
| 82550 | <1% | 106 | $1.47 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 51 | $1.21 |
| G0009 | Administration of pneumococcal vaccine | <1% | 33 | $0.68 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 24 | $0.19 |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 99 | $0.11 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 253 | $0.02 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 202 | $0.02 |
| 91301 | <1% | 1,816 | $0.01 | |
| 90744 | 0% | 947 | $0.00 | |
| 96376 | 0% | 39 | $0.00 | |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 38 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 46 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 15 | $0.00 |
| 90716 | 0% | 79 | $0.00 | |
| 86308 | 0% | 12 | $0.00 | |
| 90732 | 0% | 13 | $0.00 | |
| 0134A | 0% | 44 | $0.00 | |
| J2060 | Injection, lorazepam, 2 mg | 0% | 33 | $0.00 |
| 91307 | 0% | 186 | $0.00 | |
| 90696 | 0% | 16 | $0.00 | |
| 91306 | 0% | 131 | $0.00 | |
| 0064A | 0% | 131 | $0.00 | |
| 0124A | 0% | 86 | $0.00 | |
| 91300 | 0% | 115 | $0.00 | |
| 90685 | 0% | 12 | $0.00 | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | 0% | 44 | $0.00 |
| 91312 | 0% | 86 | $0.00 | |
| 90707 | 0% | 165 | $0.00 | |
| 91313 | 0% | 43 | $0.00 | |
| 83655 | 0% | 49 | $0.00 | |
| 77080 | 0% | 14 | $0.00 | |
| 90671 | 0% | 31 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLABONTE, ROBIN (CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| York Hospital | York, ME | $105K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.